ArticleNeurology2025
Stroke, Cardiovascular Disease, and Dementia After Hospitalized TIA: The Atherosclerosis Risk in Communities Study.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Poststroke Dementia: The Rotterdam Study Shows Why Risk Factors, Stroke Severity, and Premorbid Brain Health Matter.Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesThere are inconsistent data on the long-term risk of dementia after TIA. We used the multidecade Atherosclerosis Risk in Communities (ARIC) study to examine long-term risk of incident dementia and other post-TIA outcomes.
methodsThe ARIC study recruited participants from 4 US communities-Minneapolis, MN; Jackson, MS; Forsyth County, NC; and Washington County, MD-during the years 1987-1989. Participants have been followed through in-person visits, phone calls, and hospital and death registry surveillance. Our exposure was the first hospitalized TIA event, ascertained between 1987 and 2020. We report on post-TIA incident events ascertained between 1987 and 2020, including adjudicated dementia, stroke, cardiovascular disease (CVD) events, and mortality. We used Cox proportional hazard regression modeling with TIA as a time-dependent exposure to estimate associations with outcome events. Models were adjusted for demographics and vascular risk factors.
resultsThe ARIC study enrolled 15,792 participants (27% Black) aged 45-64 years. Our analytic sample included 13,721 participants (mean age 54 years, 55.5% women) who were without history of hospitalized TIAs or the outcomes of interest at baseline. There were 536 hospitalized TIAs over a median of 29 years. Incident dementia risk almost doubled after TIA (hazard ratio [HR] 1.96; 95% CI 1.66-2.31). Participants who had a TIA were at high risk of stroke (8.14; 6.87-9.64) and CVD (1.52; 1.28-1.82) compared with those without a TIA. They were also at an elevated risk of all-cause mortality (HR 1.55; 95% CI 1.39-1.73) and CVD mortality (1.82; 1.48-2.22). A sensitivity analysis restricted to participants with TIAs but without stroke showed an elevated risk of dementia (HR 1.67; 95% CI 1.37-2.03). DISCUSSION: We report an increased risk of dementia after TIA in our multidecade cohort. The elevated risk was present after elimination of stroke as an intermediary variable. Consistent with other studies, we found an increased risk of stroke, CVD, and mortality after TIA. The clinical implications of these results are that in addition to vascular risk factor modification, clinicians should consider incorporating cognitive screening into post-TIA follow-up care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.